First results from POSITIVE study: Young women with breast can safely have a baby BIGagainstBC 6 December 2022
AURORA, the first international molecular screening programme for metastatic breast cancer, presented at IMPAKT Breast Cancer Conference Monet St Juste 23 September 2022
New Treatment Option for Young Women with Hormone-Sensitive Breast Cancer Monet St Juste 23 September 2022
ALTTO Test of Dual HER2 Blockade Finds Single Agent – Trastuzumab – Remains the Gold Standard Monet St Juste 23 September 2022
Opening of international PANACEA study of patients with HER2+ breast cancer Monet St Juste 23 September 2022
Belgian Dr. Martine Piccart has received prestigious international Brinker Award for Scientific Distinction in Clinical Research Monet St Juste 23 September 2022
Pfizer Awards Breast International Group (BIG) $1 Million Research Grant to Support Non‐Drug Related Breast Cancer Research Monet St Juste 23 September 2022
New England Journal of Medicine” publishes results of MINDACT clinical trial The 70-gene test (Mammaprint®) can significantly reduce use of chemotherapy among breast cancer patients and has the potential to change clinical practice: 46% of early stage breast cancer patients classified as high-risk by traditional methods can avoid chemotherapy Monet St Juste 23 September 2022
Phase III APHINITY study shows Roche’s Perjeta® regimen helped people with an aggressive type of early breast cancer live longer without their disease returning compared to Herceptin® and chemotherapy Monet St Juste 23 September 2022
APHINITY study shows Roche’s Perjeta®-based regimen reduced the risk of invasive cancer returning compared to Herceptin® and chemotherapy in HER2-positive early breast cancer Monet St Juste 23 September 2022